Article
RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.
Cancer science - 1 Feb 2022
Masuda Tatsuya, Maeda Shintaro, Shimada Sae, Sakuramoto Naoya, Morita Ken, Koyama Asami, Suzuki Kensho, Mitsuda Yoshihide, Matsuo Hidemasa, Kubota Hirohito, Kato Itaru, Tanaka Kuniaki, Takita Junko, Hirata Masahiro, Kataoka Tatsuki R, Nakahata Tatsutoshi, Adachi Souichi, Hirai Hideyo, Mizuta Shuichi, Naka Kazuhito, Imai Yoichi, Kimura Shinya, Sugiyama Hiroshi, Kamikubo Yasuhiko
Abstract excerpt
The emergence of tyrosine kinase inhibitors as part of a front-line treatment has greatly improved the clinical outcome of the patients with Ph+ acute lymphoblastic leukemia (ALL). However, a portion of them still become refractory to the therapy mainly through acquiring mutations in the BCR-ABL1 gene, necessitating a novel strategy to treat tyrosine kinase inhibitor (TKI)-resistant Ph+ ALL cases. In this report,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.